µÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
IGCS | µÏÍþÖƵÏÍþ¹ú¼ÊB7-H4 ADCÖÎÁƲ¬Ä͵ÏÍþ¹ú¼ÊÂѳ²°©¢òÆÚÑо¿½á¹ûÈëÑ¡¿ÚÍ·±¨¸æ
·¢²¼ÈÕÆÚ£º2025/11/11
×ÖºÅ

µÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£¬03692.HK£©½ñÈÕÐû²¼£¬¹«Ë¾×ÔÖ÷Ñз¢µÄB7-H4°ÐÏò¿¹Ìå-µÏÍþ¹ú¼ÊÎïżÁªÎADC£©×¢ÉäÓÃHS-20089£¨ºÏ×÷·½´úÂ룺GSK5733584£©£¬ÓÃÓÚ²¬Ä͵ÏÍþ¹ú¼ÊÂѳ²°©£¨PROC£©»¼ÕßÖÎÁƵÄIIÆÚÑо¿½á¹ûÓÚ2025 Äê 11 Ô 5¡ª7 ÈÕÔÚÄÏ·Ç¿ªÆÕ¶ØÊÀ¼Í³Ç»áÒéÖÐÐľÙÐеÄ2025Äê¹ú¼Ê¸¾¿Æ°©Ö¢Ñ§»á£¨IGCS£©È«Çò»áÒéÉÏÒÔ¿ÚÍ·±¨¸æµÄÐÎʽÔÙ·¢±í¡£´ËÇ°£¬¸ÃÑо¿½á¹ûÒÑÓÚ2025ÄêÅ·ÖÞÖ×ÁöÄÚ¿Æѧ»á£¨ESMO£©Äê»áÉÏÊ×·¢¡£

 ¾ßÌåÐÅÏ¢ÈçÏ£º

±¾´Î´ó»áµÄÑо¿½á¹ûÏÔʾ£¬½ØÖÁÊý¾Ý½ØÖ¹ÈÕÆÚ£¨2025Äê6ÔÂ20ÈÕ£©£¬ HS-20089ÔÚδɸѡB7-H4±í´ïµÄÇé¿öÏ£¬ÔÚ¾­¶àÏßÖÎÁÆʧ°ÜµÄ²¬Ä͵ÏÍþ¹ú¼ÊÂѳ²°©£¨PROC£©»¼ÕßÖÐÕ¹ÏÖ³öÁîÈ˹ÄÎèµÄÁÆЧ¡£ÔÚËùÓнÓÊܹýHS-20089 4.8mg/kgÖÎÁƵÄPROC»¼ÕßÖУ¬ÖÐλËæ·Ãʱ¼äΪ11.5¸öÔ£¬È·ÈϵĿ͹ۻº½âÂÊ£¨ORR£©Îª48.5%£¬»º½â³ÖÐøʱ¼ä£¨DoR£©´ï6.8¸öÔ£»ÖÐλÎÞ½øÕ¹Éú´æÆÚ£¨mPFS£©Îª6.4¸öÔ£¬ÖÐλ×ÜÉú´æÆÚ£¨mOS£©Îª14.6¸öÔ¡£HS-20089×¢ÉäÒºµÄ°²È«ÐÔÌØÕ÷ÓëIÆÚÑо¿½á¹ûÒ»Ö£¬Î´¹Û²ìµ½¼äÖÊÐԷβ¡µÄÐźÅ¡£ÉÏÊöÁÙ´²Ñо¿½á¹ûÖ§³Ö¸ÃµÏÍþ¹ú¼ÊÎïÔÚPROC»¼ÕßÖеĽøÒ»²½¿ª·¢£¬Ä¿Ç°Ïà¹ØµÄ¢óÆÚÑо¿£¨NCT06855069)ÕýÔÚ½øÐÐÖС£

¸ü¶àÑо¿ÐÅÏ¢£º¡¶ESMO | µÏÍþÖƵÏÍþ¹ú¼ÊHS-20089(B7-H4 ADC)ÓÃÓÚ²¬Ä͵ÏÍþ¹ú¼ÊÂѳ²°©£¨PROC£©»¼ÕßÖÎÁƵĢòÆÚÑо¿½á¹û·¢²¼¡·¡£


¹ØÓÚHS-20089

HS-20089ÊÇÓɵÏÍþÖƵÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄB7-H4°ÐÏòADC¡£½ØÖÁÄ¿Ç°£¬HS-20089ÓÃÓÚÖÎÁÆÂѳ²°©ÊÊÓ¦Ö¢ÒÑÔÚÖйú½øÈëIIIÆÚÁÙ´²Ñо¿½×¶Î£¬ÁíÓÐÓÃÓÚÖÎÁÆ×Ó¹¬ÄÚĤ°©¼°ÆäËûʵÌåÁöµÄPoC¸ÅÄîÑéÖ¤ÁÙ´²Ñо¿ÕýÔÚ½øÐС£ 

2023Äê10Ô£¬µÏÍþÖƵÏÍþ¹ú¼ÊÊÚÓè¸ðÀ¼ËØÊ·¿Ë¿ª·¢¡¢Éú²ú¼°ÉÌÒµ»¯HS-20089È«Çò¶ÀÕ¼Ðí¿ÉȨÀû£¨²»º¬Öйú´ó½¡¢Ïã¸Û¡¢°ÄÃż°Ì¨ÍåµØÇø£©¡£GSK ÕýÔÚͨ¹ýÈ«Çò¿ª·¢¼Æ»®Íƽø GSK5733584£¬Ä¿Ç°ÕýÔÚÈ«Çò·¶Î§ÄÚ½øÐÐµÄ I ÆÚÁÙ´²ÊÔÑ飬°üÀ¨ BEHOLD-1£¨NCT06431594£©ºÍ BEHOLD-2£¨NCT06796907£©Ñо¿¡£

2025Äê5Ô£¬HS-20089»ñNMPAÅú×¼ÄÉÈëÍ»ÆÆÐÔÖÎÁƵÏÍþ¹ú¼ÊÎÄⶨÊÊӦ֢ΪÓÃÓÚº¬²¬Ä͵ÏÍþ¹ú¼Ê¸´·¢ÉÏƤÐÔÂѳ²°©¡¢ÊäÂѹܰ©»òÔ­·¢ÐÔ¸¹Ä¤°©»¼Õß¡£

¹ØÓÚÂѳ²°©

Âѳ²°©£¨OC£©ÊÇ×î³£¼ûµÄ¸¾¿Æ¶ñÐÔÖ×ÁöÖ®Ò»£¬2022Ä꣬ȫÇòÔ¼Õï¶Ï³ö324,603ÀýÂѳ²°©Ð²¡Àý£¬Ê¹Æä³ÉΪŮÐÔÖеڰ˴󳣼û¶ñÐÔÖ×Áö¡£¸ÃÄêÔ¼ÓÐ206,956ÀýÂѳ²°©ËÀÍö£¬Âѳ²°©³ÉΪŮÐÔ°©Ö¢Ïà¹ØËÀÍöµÄµÚ°Ë´óÔ­Òò¡£ÔÚÖйú£¬2022ÄêÂѳ²°©µÄ·¢²¡ÊýΪ61,060Àý£¬ËÀÍöÈËÊýΪ32,646Àý[1] ¡£

ÊÖÊõÁªºÏÒÔ²¬Îª»ù´¡µÄ»¯ÁÆÊÇÄ¿Ç°Âѳ²°©µÄ±ê×¼ÖÎÁÆ·½Ê½£¬µ«¾ø´ó²¿·ÖÍíÆÚ»¼Õß»áÔÚ3ÄêÄÚ¸´·¢£¬²¢×îÖÕ»á¶Ô²¬À໯ÁƲúÉúÄ͵ÏÍþ¹ú¼ÊÐÔ£¬²¬Ä͵ÏÍþ¹ú¼Ê¸´·¢Âѳ²°©£¨PROC£©µÄÁÙ´²ÖÎÁÆÊֶκÍÁÆЧ¾ùÊ®·ÖÓÐÏÞ¡£¸ù¾Ý½üÄêÀ´¿ªÕ¹µÄ¢óÆÚËæ»ú¶ÔÕÕÑо¿ÖеĶÔÕÕ×飨·Ç²¬µ¥µÏÍþ¹ú¼Ê»¯ÁÆ£©Êý¾ÝÏÔʾ£¬·Ç²¬µ¥µÏÍþ¹ú¼Ê»¯ÁÆÂѳ²°©µÄ¿Í¹Û»º½âÂÊ£¨ORR£©½ö4%~15.9%£¬ÖÐλÎÞ½øÕ¹Éú´æÆÚ£¨mPFS£©½ö3.4~3.98¸öÔ¡£¶ÔÓÚ½ÓÊܹý1ÖÁ2ÏßÖÎÁƵĻ¼Õߣ¬·Ç²¬»¯ÁƽáºÏ±´·¥Öéµ¥¿¹µÄORRΪ27.3%£¬mPFSÑÓ³¤ÖÁ6.7¸öÔ£¬ÖÐλÉú´æÆÚ£¨mOS£©´ïµ½16.6¸öÔ¡£¾¡¹ÜPFSÏÔÖøÑÓ³¤£¬µ«OSÓë·Ç²¬»¯ÁÆÏà±ÈÎÞÃ÷ÏÔ»ñÒæ[2-6] ¡£Ä¿Ç°¸Ã¼²²¡ÈÔ´æÔÚ¾Þ´óδ±»Âú×ãµÄÁÙ´²ÐèÇó£¬Ø½´ýÑ°ÕÒ¸üΪÓÐЧµÄÖÎÁÆ·½Ê½¡£


¹ØÓÚIGCS 2025

µÚ24½ì¹ú¼Ê¸¾¿ÆÖ×ÁöЭ»áÈ«ÇòÄê»á£¨IGCS 2025£©ÓÚ 2025Äê11ÔÂ5ÈÕÖÁ7ÈÕÔÚÄÏ·Ç¿ªÆնصÄÊÀ¼Í³Ç»áÒéÖÐÐľٰ죬²Î»áÈËÔ±°üÀ¨¸¾¿ÆÖ×Áöѧ¼Ò¡¢Ö×Áö¿ÆÒ½Éú¡¢¿Æѧ¼ÒµÈÖÚ¶àÏà¹ØÁìÓòÈËÊ¿¡£»áÒéÄÚÈݷḻ£¬º­¸Ç¸¾¿ÆÖ×Áöѧ¸÷·½Ã棬×÷ΪÊ×´ÎÔÚ·ÇÖÞ´ó½¾Ù°ìµÄÈ«Çò IGCS »áÒ飬ΪÓë¸÷ѧ¿Æ¶¥¼âר¼Ò½»Á÷ÌṩÁ˶ÀÌØ»ú»á£¬Íƶ¯¸¾¿ÆÖ×ÁöѧÑо¿Óëʵ¼ù·¢Õ¹¡£

²Î¿¼ÎÄÏ×£º

[1]International Agency for Research on Cancer. (2024). Cancer TODAY: GLOBOCAN 2022 (version 1.1). Retrieved April 26, 2025, from Global Cancer Observatory

[2]Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Lancet Oncol. Jul 2021;22(7):1034-1046.

[3] Gaillard S, Oaknin A, Ray-Coquard I, et al. Gynecol Oncol. Nov 2021;163(2):237-245.

[4] Hamanishi J, Takeshima N, Katsumata N, et al. J Clin Oncol. Nov 20 2021;39(33):3671-3681.

[5] Pujade-Lauraine E, Hilpert F, Weber B, et al.

[6] Moore KN, Angelergues A, Konecny GE, et al. N Engl J Med. Dec 7 2023;389(23):2162-2174.


¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÔÚÖйú²úÉúÏúÊÛÊÕÈëµÄ´´ÐµÏÍþ¹ú¼Ê¹²7¿î£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖƵÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£

ÃâÔðÉùÃ÷

±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£±¾ÎÄÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£

Ç°Õ°ÐÔ˵Ã÷

±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£

    ¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿